Therefore 36 tumors (30.8%) were classified as Luminal A, 28 (23.9%) as Luminal B, 9 (7.7%) as HER2 overexpressing, and 44 (37.6%) as Triple Negative Breast Cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.